2023 ASCO GU Bladder Highlights With Michiel Van der Heijden, MD, PhD

By The Uromigos - Last Updated: March 7, 2023

Michiel Van der Heijden, MD, PhD, joined The Uromigos to review bladder cancer presentations from the 2023 ASCO GU Cancers Symposium, including the phase 1B NABUCCO trial on the use of high- or low-dose preoperative ipilimumab with nivolumab for stage III urothelial cancer, as well as his paper on the use of predictive biomarkers for survival benefit with ramucirumab in the RANGE trial.
Dr. Van der Heijden is a medical oncologist research group leader at The Netherlands Cancer Institute, focusing on the improvement of bladder cancer treatment.

Post Tags:Uromigos-ASCO GUUromigos-Bladder Cancer